BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

735 related articles for article (PubMed ID: 21521830)

  • 1. Recent progress in the diagnosis and treatment of ovarian cancer.
    Jelovac D; Armstrong DK
    CA Cancer J Clin; 2011; 61(3):183-203. PubMed ID: 21521830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the management of epithelial ovarian cancer.
    Berkenblit A; Cannistra SA
    J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.
    Al Bakir M; Gabra H
    Br Med Bull; 2014 Dec; 112(1):57-69. PubMed ID: 25473022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?
    Tan DS; Kaye SB
    Am Soc Clin Oncol Educ Book; 2015; ():114-21. PubMed ID: 25993149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Ledermann JA; Raja FA; Fotopoulou C; Gonzalez-Martin A; Colombo N; Sessa C;
    Ann Oncol; 2013 Oct; 24 Suppl 6():vi24-32. PubMed ID: 24078660
    [No Abstract]   [Full Text] [Related]  

  • 7. Ovarian cancer.
    Hennessy BT; Coleman RL; Markman M
    Lancet; 2009 Oct; 374(9698):1371-82. PubMed ID: 19793610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
    Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
    Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
    J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer.
    Jayson GC; Kohn EC; Kitchener HC; Ledermann JA
    Lancet; 2014 Oct; 384(9951):1376-88. PubMed ID: 24767708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The molecular biology of epithelial ovarian cancer].
    Leary A; Pautier P; Tazi Y; Morice P; Duvillard P; Gouy S; Uzan C; Gauthier H; Balleyguier C; Lhommé C
    Bull Cancer; 2012 Dec; 99(12):1161-73. PubMed ID: 23238064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Therapies for Ovarian Cancer.
    Grunewald T; Ledermann JA
    Best Pract Res Clin Obstet Gynaecol; 2017 May; 41():139-152. PubMed ID: 28111228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of second-look laparotomy for surgically confirmed early-stage epithelial ovarian cancer: a multicenter retrospective study.
    Sato N; Akahira J; Kitamura T; Aoki M; Yoshinaga K; Okamura C; Utsunomiya H; Shimizu T; Niikura H; Ito K; Okamura K; Yaegashi N
    Int J Clin Oncol; 2003 Feb; 8(1):40-4. PubMed ID: 12601541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
    Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
    Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Epithelial ovarian cancer - a change of paradigm].
    Heinzelmann-Schwarz V
    Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCAness profile of sporadic ovarian cancer predicts disease recurrence.
    Wysham WZ; Mhawech-Fauceglia P; Li H; Hays L; Syriac S; Skrepnik T; Wright J; Pande N; Hoatlin M; Pejovic T
    PLoS One; 2012; 7(1):e30042. PubMed ID: 22253870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rare epithelial tumors arising in or near the ovary: a review of the risk factors, presentation, and future treatment direction for ovarian clear cell and mucinous carcinoma.
    Jain A; Seiden MV
    Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Clinical Outcomes of
    Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.